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Alert readers, authors and reviewers of papers in BJC will have
noticed new names among our Subject Editors. Jim Cassidy
(University of Glasgow) has joined us as Clinical Editor, Richard
Houlston (Institute of Cancer Research, Sutton) now edits papers
in Genetics and Genomics, and Bryan Leyland-Jones (McGill
University, Montreal) has just begun to edit Experimental
Therapeutics. Moreover, Chris Boshoff is now properly acknowl-
edged as our Reviews Editor, a task he has been doing
unassumingly, with vision, keen judgement, and good taste, since
we initiated our series of minireviews 3 years ago.
These changes mean that it is time to relieve three old friends of
their duties: Robert Hawkins (University of Manchester) has been
our Clinical Editor for rather more than 8 years, John Double
(University of Bradford) has looked after Experimental Therapeu-
tics for almost as long, and Carlo Croce (Thomas Jefferson
University, Philadelphia) began to help develop the then new
Genetics and Genomics Section 3 years ago. We are immensely
grateful for their hard work and for their very fine evaluation and
editorship of papers. They will be much missed as colleagues and
for the intellectual contribution that they have made to the success
of BJC as a wide-ranging, cutting-edge journal in the expanding
and increasingly busy arena of cancer research. I am particularly
indebted to Robert Hawkins for facilitating considerable growth in
the number and quality of clinical papers submitted to BJC, and for
the increasingly lively engagement of the clinical community via
letters, editorials, and mini-reviews on topics ranging from
original research findings to policy matters. We heartily welcome
this development and hope to see it continue. John Double built
upon the heritage of my predecessor, the late Ged Adams. They
made BJC the natural home of some of the very best papers, taking
promising research findings through experimental systems and
pharmacology to establish that they had potential for improved
treatment for patients. The BJC welcomes and encourages papers
from those who work with ‘translation’ as their goal. Moreover,
John has ever been mindful that while the use of animals is crucial
to advances in some areas of cancer research, BJC publishes only
those papers reporting research that meets stringent standards of
ethics and animal welfare.
Our outgoing Subject Editors have set high standards that I
know our new colleagues are keen to uphold and enhance.
Supported by sophisticated on-line systems, we have been able to
improve the speed at which papers are reviewed and published.
BJC intends to continue in these directions and to enhance the
publication service that it offers to the cancer research
community. At the heart of our activities, we have a large
number of dedicated regular reviewers, to whom we owe
immeasurable thanks; only a very few of them can be listed on
the Editorial Board. Peer review remains the pivotal means of
selecting and honing the best research, and we are deeply
indebted and grateful to all our colleagues who spend valuable
hours on this process.
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